Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 31.4% year on year to $209.4 million. The company’s full-year revenue guidance of$780 million at the midpoint came in 3.8% above analysts’ estimates. Its non-GAAP profit of $2.25 per share was 21% above analysts’ consensus estimates. Is now the time to buy COLL? Find out in our full research report (it’s free for active Edge members). Collegium Pharmaceutical (COLL) Q3 CY202 ...